Document is current
Any future updates will be listed below
-
Authors
Jussing, Emma https://orcid.org/0000-0003-4697-732X
Ferrat, Mélodie
Moein, Mohammad M.
Alfredéen, Henrik
Tegnebratt, Tetyana
Bratteby, Klas
Samén, Erik
Feldwisch, Joachim
Altena, Renske
Axelsson, Rimma
Tran, Thuy A.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05619016 at ClinicalTrials.govDocuments that mention this clinical trial
Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer
https://doi.org/10.1186/s41181-023-00226-y
-
Funding
Funding for this research was provided by:
Sjöbergsstiftelsen (929649)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 13 October 2023
Accepted: 15 November 2023
First Online: 22 November 2023
Declarations
:
: Not applicable. No animal- or clinical studies were conducted in this report. The results from this study were submitted in an IMPD along with a CTA for the clinical study (NCT05619016), and the CTA was approved before production for the clinical trial.
: Not applicable.
: JF is an employee of Affibody AB and CMC director for the ABY-025 program. Affibody AB holds the intellectual property rights and trademarks for Affibody molecules. The remaining authors have no competing interests to declare.
